| Clinical pharmacokinetics of metformin GG Graham, J Punt, M Arora, RO Day, MP Doogue, J Duong, TJ Furlong, ... Clinical pharmacokinetics 50, 81-98, 2011 | 1361 | 2011 |
| Clearance concepts in pharmacokinetics M Rowland, LZ Benet, GG Graham Journal of pharmacokinetics and biopharmaceutics 1 (2), 123-136, 1973 | 959 | 1973 |
| Mechanism of action of paracetamol GG Graham, KF Scott American journal of therapeutics 12 (1), 46-55, 2005 | 818 | 2005 |
| The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings GG Graham, MJ Davies, RO Day, A Mohamudally, KF Scott Inflammopharmacology 21, 201-232, 2013 | 712 | 2013 |
| Stereoselective disposition of ibuprofen enantiomers in man. EJ Lee, KM Williams, R Day, G Graham, D Champion British journal of clinical pharmacology 19 (5), 669-674, 1985 | 359 | 1985 |
| A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients? MHH Lee, GG Graham, KM Williams, RO Day Drug safety 31, 643-665, 2008 | 330 | 2008 |
| Non-steroidal anti-inflammatory drugs (NSAIDs) RO Day, GG Graham Bmj 346, 2013 | 259 | 2013 |
| Tolerability of paracetamol GG Graham, KF Scott, RO Day Drug safety 28 (3), 227-240, 2005 | 259* | 2005 |
| Antibacterial actions of secreted phospholipases A2. Review TJ Nevalainen, GG Graham, KF Scott Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2008 | 247 | 2008 |
| Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol RO Day, GG Graham, M Hicks, AJ McLachlan, SL Stocker, KM Williams Clinical pharmacokinetics 46, 623-644, 2007 | 226 | 2007 |
| Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012 SN Ramasamy, CS Korb-Wells, DRW Kannangara, MWH Smith, N Wang, ... Drug safety 36, 953-980, 2013 | 222 | 2013 |
| Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin WH Chung, WC Chang, SL Stocker, CG Juo, GG Graham, MHH Lee, ... Annals of the rheumatic diseases 74 (12), 2157-2164, 2015 | 216 | 2015 |
| Emerging roles for phospholipase A2 enzymes in cancer KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ... Biochimie 92 (6), 601-610, 2010 | 186 | 2010 |
| Concentration‐response relationships for salicylate‐induced ototoxicity in normal volunteers. RO Day, GG Graham, D Bieri, M Brown, D Cairns, G Harris, J Hounsell, ... British journal of clinical pharmacology 28 (6), 695-702, 1989 | 145 | 1989 |
| Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function JK Duong, SS Kumar, CM Kirkpatrick, LC Greenup, M Arora, TC Lee, ... Clinical pharmacokinetics 52, 373-384, 2013 | 143 | 2013 |
| Oncogenic action of secreted phospholipase A2 in prostate cancer P Sved, KF Scott, D McLeod, NJC King, J Singh, T Tsatralis, B Nikolov, ... Cancer research 64 (19), 6934-6940, 2004 | 129 | 2004 |
| The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis JK Duong, TJ Furlong, DM Roberts, GG Graham, JR Greenfield, ... Drug safety 36, 733-746, 2013 | 120 | 2013 |
| Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis GG Graham, GD Champion, RO Day, PD Paull Clinical Pharmacology & Therapeutics 22 (4), 410-420, 1977 | 116 | 1977 |
| Mechanisms of action of paracetamol and related analgesics GG Graham, KF Scott Inflammopharmacology 11, 401-413, 2003 | 115 | 2003 |
| Pharmacology of benzydamine PA Quane, GG Graham, JB Ziegler Inflammopharmacology 6, 95-107, 1998 | 115 | 1998 |
Richard O. DayProfessor of Clinical Pharmacology, University of New South Wales and St Vincent's Hospital, SydneyVerified email at unsw.edu.au
